Skip to main content

Table 3 Results of regression analysis of processeda quarterly health costs in first year after baseline (N = 5463)

From: Telemedical monitoring of patients with chronic heart failure has a positive effect on total health costs

 

Reference

Estimate

[in €]

CI 95%

P-value

2.5%

97.5%

Study group

Control group

−276.04

− 573.18

21.10

0.0686

Residential area (Berlin vs. rural)

Rural

180.81

−49.03

410.65

0.1231

Interaction: Group x Residential area

257.77

−131.35

646.90

0.1941

Age group

 46–50 years

41–45 years

878.30

− 652.97

2409.58

0.2609

 51–55 years

41–45 years

669.75

− 749.92

2089.43

0.3551

 56–60 years

41–45 years

641.50

−743.15

2026.14

0.3638

 61–65 years

41–45 years

448.94

− 905.54

1803.43

0.5159

 66–70 years

41–45 years

828.90

−502.34

2160.14

0.2223

 71–75 years

41–45 years

1117.78

− 210.13

2445.69

0.0990

 76–80 years

41–45 years

1160.55

− 167.31

2488.41

0.0867

 81–85 years

41–45 years

973.17

− 359.70

2306.04

0.1524

 86–90 years

41–45 years

876.95

− 471.87

2225.77

0.2025

 91–95 years

41–45 years

1168.45

− 340.20

2677.11

0.1290

Sex

Male

−73.85

−245.19

97.49

0.3982

NYHA class

NYHA II

NYHA I

18.38

− 793.15

829.91

0.9646

NYHA III

NYHA I

210.53

−600.60

1021.65

0.6109

NYHA IV

NYHA I

398.18

−419.09

1215.45

0.3396

 Hospitalizations related to CHF

(continuous)

52.03

−51.72

155.79

0.3256

 Baseline health costs

(continuous)

0.37

0.34

0.40

< 0.0001***

Intake of medication related to CHF (yes / no by groups of agents)

 Angiotensin-converting enzyme

no

− 139.92

−313.52

33.69

0.1142

 Beta-blocker

no

−279.06

− 450.13

− 107.98

0.0014**

 Renin-inhibitors

no

−75.07

− 734.15

584.01

0.8233

 Cardiac glycosides

no

147.81

−81.40

377.01

0.2062

 Diuretics

no

394.65

214.89

574.40

< 0.0001***

 AT1 receptor blocker

no

−25.55

− 247.64

196.54

0.8216

Mental and behavioral disorders (yes / no by blocks of ICD-10 Chapter V)

 F00 – F09 (Organic, including symptomatic, mental disorders)

no

465.72

173.79

757.65

0.0018**

 F10 – F19 (Mental and behavioral disorders due to psychoactive substance use)

no

39.64

− 257.67

336.94

0.7938

 F20 – F29 (Schizophrenia, schizotypal and delusional disorders)

no

−34.52

− 936.45

867.41

0.9402

 F30 – F39 (Mood [affective] disorders)

no

109.85

−120.77

340.48

0.3504

 F40 – F49 (Neurotic, stress-related and somatoform disorders)

no

51.25

− 188.92

291.42

0.6757

 F50 – F59 (Behavioral syndromes associated with physiological disturbances and physical factors)

no

343.92

− 130.81

818.64

0.1556

 F60 – F69 (Disorders of adult personality and behavior)

no

−120.35

− 859.94

619.25

0.7497

 F70 – F79 (Mental retardation)

no

321.91

−921.90

1565.71

0.6119

 F80 – F89 (Disorders of psychological development)

no

 F90 – F98 (Behavioral and emotional disorders with onset usually occurring in childhood and adolescence)

no

612.00

− 991.08

2215.09

0.4542

 F99 – F99 (Unspecified mental disorders)

no

490.90

− 1333.73

2315.52

0.5979

Intercept

249.86

− 1318.15

1817.88

0.7548

  1. aHealth costs after performing the excluding-and-capping algorithm, Significance codes: ***p < 0.001, **p < 0.01, *p < 0.05